Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Resources / EDRN Standard Operating Procedures (SOP) / Assays / Immunohistochemistry / Immunoperoxidase Automated Procedure (Ventana)

Immunoperoxidase Automated Procedure (Ventana)

  1. Cut tissue sections at 3-5 microns and mount on appropriate control box slides.
  2. Bake slides for 30 minutes in 70°C - 90°C oven.
  3. Label slides with barcode labels indicating antibody.
  4. Place slides inside Ventana stainer and load all necessary antibodies and reagents.
  5. Start machine.
  6. Remove slides when finished and wash in warm soapy water (Dawn concentrate dishwashing detergent) to remove oil coating.
  7. Counter stain with Gills I hematoxylin for 1 minute then blue in Lithium Carbonate solution.
  8. Wash in tap water 2-5 minutes.
  9. Dehydrate slides.

    Rinse 15-20 dips in

    • 2 changes 95% ETOH
    • 2 changes ABS ETOH
    • 3 changes Xylene
  10. Coverslip on automatic coverslipper.
New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.